Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Oesophageal cancer is a common cause of cancer death worldwide. Curative treatment involves chemotherapy and surgery but has significant risks. Therefore, patient selection and improving physical fitness to withstand such major treatment is important to reduce the risk of complications. Physical fitness is traditionally measured by a specialised exercise test called Cardiopulmonary exercise testing (CPET), which can take up to one hour and requires specialised staff and expensive equipment such as a graded exercise bike or treadmill. Seismofit is a small device (smaller than a smartphone) used to estimate fitness in patients in under three minutes while lying down at rest. It measures the vibrations generated by the heart and, together with patient height, weight, age, and gender, accurately estimates fitness using an algorithm developed in healthy patients. The device has never been tested in a large group of oesophageal cancer patients to see if it can be used to predict complications in patients undergoing cancer treatment. In this study, patients undergoing Oesophageal cancer treatment with chemotherapy or chemoradiotherapy and surgery will have Seismofit measurements at various points during their treatment to see if we can predict complications and hospital stay. Secondly, this study will also evaluate the accuracy of Seismofit compared to the gold standard CPET results in cancer patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zdiagnozowany rak przełyku kwalifikujący się do radykalnego leczenia
- •Pacjent będący kandydatem do chemioterapii i operacyjnego usunięcia raka
- •Zdolność do wyrażenia świadomej zgody na udział w badaniu
✗ Disqualifies
- •Ciąża
- •Wiek poniżej 18 lat
- •Operacja bez wcześniejszej chemioterapii
- •Pacjenci z wszczepionym rozrusznikiem serca lub kardiowerterem-defibrylatorem
- •Ocenieni przez zespół lekarzy jako nienadający się do operacji
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Royal Surrey NHS Foundation Trust
Guildford, United Kingdom
Guy's and St Thomas' Hospital NHS Foundation Trust
London, United Kingdom
Royal Marsden NHS Foundation Trust
London, United Kingdom
University Hospital Southampton
Southampton, United Kingdom
Trial contact
Kesav Aditya Vijayagopal, DMS
Andrew Davies, MD FRCS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.